KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Other Operating Expenses (2016 - 2026)

Bristol Myers Squibb has reported Other Operating Expenses over the past 18 years, most recently at $4.0 billion for Q1 2026.

  • Quarterly Other Operating Expenses fell 9.23% to $4.0 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $21.2 billion through Mar 2026, down 8.34% year-over-year, with the annual reading at $21.6 billion for FY2025, 41.66% down from the prior year.
  • Other Operating Expenses was $4.0 billion for Q1 2026 at Bristol Myers Squibb, down from $6.3 billion in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $18.3 billion in Q1 2024 and troughed at $4.0 billion in Q1 2026.
  • The 5-year median for Other Operating Expenses is $5.3 billion (2023), against an average of $6.1 billion.
  • Year-over-year, Other Operating Expenses surged 308.54% in 2024 and then tumbled 76.04% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $4.8 billion in 2022, then increased by 10.08% to $5.3 billion in 2023, then soared by 30.24% to $6.8 billion in 2024, then decreased by 8.41% to $6.3 billion in 2025, then crashed by 36.41% to $4.0 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Other Operating Expenses are $4.0 billion (Q1 2026), $6.3 billion (Q4 2025), and $4.8 billion (Q3 2025).